 Taeju Park
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-crk | 17 | 2024 | 17 | 5.750 |
Why?
| | Adaptor Proteins, Signal Transducing | 13 | 2024 | 41 | 4.280 |
Why?
| | Nuclear Proteins | 11 | 2024 | 52 | 2.330 |
Why?
| | Animals | 35 | 2022 | 741 | 1.510 |
Why?
| | Nerve Tissue Proteins | 6 | 2014 | 25 | 1.340 |
Why?
| | Fibroblasts | 5 | 2018 | 26 | 1.240 |
Why?
| | Cell Movement | 5 | 2023 | 71 | 1.180 |
Why?
| | Chromaffin Cells | 7 | 2003 | 7 | 1.160 |
Why?
| | Crk-Associated Substrate Protein | 3 | 2024 | 3 | 1.110 |
Why?
| | src Homology Domains | 2 | 2024 | 2 | 1.080 |
Why?
| | Signal Transduction | 12 | 2022 | 133 | 1.020 |
Why?
| | Phosphotyrosine | 1 | 2024 | 1 | 0.970 |
Why?
| | Peptides | 1 | 2024 | 11 | 0.960 |
Why?
| | Cell Adhesion Molecules, Neuronal | 3 | 2014 | 4 | 0.960 |
Why?
| | Serine Endopeptidases | 3 | 2014 | 5 | 0.960 |
Why?
| | Extracellular Matrix Proteins | 3 | 2014 | 13 | 0.950 |
Why?
| | Glioblastoma | 2 | 2021 | 17 | 0.940 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 10 | 0.780 |
Why?
| | Lens Capsule, Crystalline | 1 | 2020 | 1 | 0.740 |
Why?
| | Cytological Techniques | 1 | 2020 | 3 | 0.730 |
Why?
| | Receptors, Nicotinic | 6 | 2003 | 8 | 0.700 |
Why?
| | Mice | 13 | 2022 | 339 | 0.670 |
Why?
| | Neoplasms | 1 | 2021 | 126 | 0.650 |
Why?
| | Catecholamines | 6 | 2001 | 7 | 0.640 |
Why?
| | Cell Proliferation | 4 | 2023 | 58 | 0.630 |
Why?
| | Dendrites | 2 | 2014 | 2 | 0.620 |
Why?
| | Cell Line, Tumor | 4 | 2023 | 98 | 0.610 |
Why?
| | Calcium Channels | 6 | 2001 | 10 | 0.580 |
Why?
| | G1 Phase | 1 | 2016 | 2 | 0.580 |
Why?
| | S Phase | 1 | 2016 | 3 | 0.580 |
Why?
| | Calcium | 14 | 2003 | 40 | 0.570 |
Why?
| | Humans | 13 | 2024 | 6929 | 0.550 |
Why?
| | Neurons | 2 | 2014 | 18 | 0.540 |
Why?
| | Nicotinic Antagonists | 6 | 2001 | 8 | 0.540 |
Why?
| | Mice, Knockout | 8 | 2020 | 60 | 0.520 |
Why?
| | Calcium Channel Blockers | 6 | 2001 | 7 | 0.450 |
Why?
| | Time Factors | 5 | 2020 | 263 | 0.440 |
Why?
| | Adrenal Glands | 4 | 2001 | 6 | 0.420 |
Why?
| | Neoplasm Invasiveness | 2 | 2023 | 29 | 0.400 |
Why?
| | Phenotype | 4 | 2021 | 256 | 0.380 |
Why?
| | Norepinephrine | 10 | 2003 | 12 | 0.370 |
Why?
| | Cattle | 8 | 2003 | 24 | 0.350 |
Why?
| | Gene Knockdown Techniques | 2 | 2021 | 13 | 0.340 |
Why?
| | PC12 Cells | 8 | 2003 | 9 | 0.320 |
Why?
| | Receptors, Purinergic P1 | 2 | 1998 | 2 | 0.310 |
Why?
| | Brain | 1 | 2008 | 79 | 0.310 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 90 | 0.310 |
Why?
| | Mice, Transgenic | 3 | 2020 | 35 | 0.300 |
Why?
| | In Vitro Techniques | 3 | 2021 | 25 | 0.290 |
Why?
| | Cardiovascular Abnormalities | 1 | 2006 | 2 | 0.280 |
Why?
| | Protein Binding | 2 | 2024 | 31 | 0.280 |
Why?
| | Cleft Palate | 1 | 2006 | 14 | 0.280 |
Why?
| | Transfection | 3 | 2023 | 23 | 0.270 |
Why?
| | Rats | 11 | 2012 | 112 | 0.260 |
Why?
| | Molecular Docking Simulation | 1 | 2024 | 1 | 0.240 |
Why?
| | Neurotensin | 2 | 2003 | 2 | 0.240 |
Why?
| | Cells, Cultured | 5 | 2015 | 84 | 0.240 |
Why?
| | Receptors, Bradykinin | 1 | 2003 | 1 | 0.230 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2023 | 56 | 0.220 |
Why?
| | Acetylcholine | 1 | 2003 | 2 | 0.220 |
Why?
| | Proteins | 1 | 2003 | 27 | 0.220 |
Why?
| | Podocytes | 2 | 2014 | 12 | 0.220 |
Why?
| | RNA, Messenger | 1 | 2023 | 115 | 0.220 |
Why?
| | Cell Differentiation | 3 | 2022 | 56 | 0.220 |
Why?
| | Protein Kinase C | 2 | 2004 | 4 | 0.210 |
Why?
| | Adenosine Triphosphate | 2 | 2001 | 3 | 0.200 |
Why?
| | Clozapine | 1 | 2001 | 3 | 0.200 |
Why?
| | Camphor | 1 | 2001 | 1 | 0.200 |
Why?
| | Cytoskeleton | 1 | 2021 | 6 | 0.200 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 8 | 0.190 |
Why?
| | Neural Crest | 1 | 2022 | 51 | 0.190 |
Why?
| | Heart Defects, Congenital | 1 | 2022 | 81 | 0.190 |
Why?
| | Gene Expression Regulation | 3 | 2014 | 103 | 0.190 |
Why?
| | Mice, 129 Strain | 1 | 2020 | 2 | 0.190 |
Why?
| | Phosphorylation | 4 | 2014 | 21 | 0.190 |
Why?
| | Electric Impedance | 1 | 2020 | 3 | 0.180 |
Why?
| | Ion Channel Gating | 2 | 1997 | 3 | 0.170 |
Why?
| | Ions | 1 | 1999 | 2 | 0.170 |
Why?
| | Temperature | 1 | 1999 | 12 | 0.170 |
Why?
| | Neomycin | 1 | 1999 | 1 | 0.170 |
Why?
| | Apoptosis | 2 | 2016 | 49 | 0.170 |
Why?
| | Nicotine | 4 | 2003 | 9 | 0.160 |
Why?
| | Tritium | 5 | 2001 | 5 | 0.160 |
Why?
| | Sodium Channel Blockers | 1 | 1998 | 1 | 0.160 |
Why?
| | Amitriptyline | 1 | 1998 | 4 | 0.160 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 1998 | 5 | 0.160 |
Why?
| | Muromegalovirus | 1 | 2018 | 1 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2018 | 3 | 0.160 |
Why?
| | Killer Cells, Natural | 1 | 2018 | 12 | 0.160 |
Why?
| | Lens, Crystalline | 1 | 2018 | 1 | 0.160 |
Why?
| | Cell Shape | 1 | 2018 | 2 | 0.160 |
Why?
| | Fibroblast Growth Factors | 1 | 2018 | 30 | 0.150 |
Why?
| | Drug Interactions | 3 | 2003 | 32 | 0.150 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2016 | 1 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 4 | 0.140 |
Why?
| | Sodium | 3 | 2003 | 7 | 0.140 |
Why?
| | Cytoplasm | 1 | 2016 | 7 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 8 | 0.140 |
Why?
| | Type C Phospholipases | 3 | 2003 | 3 | 0.140 |
Why?
| | Colforsin | 1 | 1996 | 1 | 0.140 |
Why?
| | Anti-Bacterial Agents | 1 | 1999 | 243 | 0.140 |
Why?
| | Cell Line | 4 | 2015 | 79 | 0.130 |
Why?
| | Electrophysiology | 3 | 2001 | 6 | 0.130 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2015 | 1 | 0.130 |
Why?
| | Oncogene Proteins v-fos | 1 | 2015 | 1 | 0.130 |
Why?
| | Chemotaxis | 1 | 2015 | 6 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2015 | 31 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 16 | 0.130 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2022 | 8 | 0.120 |
Why?
| | Bradykinin | 4 | 2003 | 5 | 0.120 |
Why?
| | Purkinje Cells | 1 | 2014 | 2 | 0.120 |
Why?
| | Cerebellum | 1 | 2014 | 13 | 0.120 |
Why?
| | Stress Fibers | 1 | 2013 | 1 | 0.120 |
Why?
| | Depsipeptides | 1 | 2013 | 2 | 0.120 |
Why?
| | Focal Adhesions | 1 | 2013 | 2 | 0.120 |
Why?
| | Microtubules | 1 | 2013 | 5 | 0.120 |
Why?
| | Blotting, Western | 2 | 2010 | 18 | 0.110 |
Why?
| | Arylamine N-Acetyltransferase | 2 | 2004 | 18 | 0.110 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2011 | 1 | 0.100 |
Why?
| | Oncogene Protein v-crk | 1 | 2011 | 1 | 0.100 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2011 | 2 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 6 | 0.100 |
Why?
| | Mitochondria | 1 | 2011 | 10 | 0.100 |
Why?
| | Kidney Glomerulus | 1 | 2012 | 19 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2012 | 71 | 0.100 |
Why?
| | Binding Sites | 2 | 2001 | 27 | 0.100 |
Why?
| | Exocytosis | 2 | 2003 | 2 | 0.100 |
Why?
| | Lidocaine | 2 | 2003 | 6 | 0.100 |
Why?
| | Neuromuscular Junction | 1 | 2010 | 1 | 0.100 |
Why?
| | Synapses | 1 | 2010 | 2 | 0.100 |
Why?
| | Muscle Proteins | 1 | 2010 | 6 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 72 | 0.090 |
Why?
| | Chlorpromazine | 2 | 2001 | 2 | 0.090 |
Why?
| | Dopamine Antagonists | 2 | 2001 | 3 | 0.090 |
Why?
| | Phenethylamines | 3 | 2000 | 4 | 0.090 |
Why?
| | Adenosine | 3 | 2000 | 8 | 0.090 |
Why?
| | Genotype | 2 | 2014 | 408 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2008 | 47 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 2 | 2012 | 14 | 0.080 |
Why?
| | HEK293 Cells | 3 | 2014 | 32 | 0.080 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 1998 | 3 | 0.080 |
Why?
| | Dimethylphenylpiperazinium Iodide | 3 | 2001 | 3 | 0.070 |
Why?
| | Calcium Channels, L-Type | 3 | 2001 | 5 | 0.070 |
Why?
| | Potassium | 3 | 2001 | 10 | 0.070 |
Why?
| | Antigens, CD34 | 1 | 2006 | 1 | 0.070 |
Why?
| | Crosses, Genetic | 1 | 2006 | 6 | 0.070 |
Why?
| | Gene Targeting | 1 | 2006 | 5 | 0.070 |
Why?
| | Nose | 1 | 2006 | 5 | 0.070 |
Why?
| | Myocardium | 1 | 2006 | 9 | 0.070 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 11 | 0.070 |
Why?
| | Blood Vessels | 1 | 2006 | 5 | 0.070 |
Why?
| | Morphogenesis | 2 | 2018 | 9 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2003 | 96 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2003 | 26 | 0.070 |
Why?
| | Receptors, Purinergic P2 | 2 | 2001 | 2 | 0.060 |
Why?
| | Pineal Gland | 2 | 2004 | 2 | 0.060 |
Why?
| | Receptor, Bradykinin B2 | 1 | 2003 | 1 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2003 | 36 | 0.060 |
Why?
| | Two-Hybrid System Techniques | 1 | 2003 | 1 | 0.060 |
Why?
| | Ubiquitin | 1 | 2003 | 1 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2003 | 4 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 7 | 0.060 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2003 | 11 | 0.060 |
Why?
| | Pseudopodia | 2 | 2014 | 6 | 0.060 |
Why?
| | Anesthetics, Local | 1 | 2003 | 2 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2003 | 15 | 0.060 |
Why?
| | Membrane Proteins | 2 | 2014 | 53 | 0.050 |
Why?
| | Male | 3 | 2006 | 3367 | 0.050 |
Why?
| | Cyclic AMP | 3 | 1999 | 4 | 0.050 |
Why?
| | Female | 2 | 2012 | 3534 | 0.050 |
Why?
| | GTP-Binding Proteins | 2 | 1999 | 7 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 3 | 2012 | 47 | 0.050 |
Why?
| | Alkenes | 1 | 2001 | 1 | 0.050 |
Why?
| | GABA Antagonists | 1 | 2001 | 2 | 0.050 |
Why?
| | Nicotinic Agonists | 1 | 2001 | 3 | 0.050 |
Why?
| | Anti-Infective Agents, Local | 1 | 2001 | 8 | 0.050 |
Why?
| | Inositol 1,4,5-Trisphosphate | 2 | 1999 | 2 | 0.050 |
Why?
| | Plants, Medicinal | 1 | 2000 | 1 | 0.050 |
Why?
| | Sympathomimetics | 1 | 2000 | 2 | 0.050 |
Why?
| | Estradiol | 1 | 2000 | 10 | 0.050 |
Why?
| | Mutation | 2 | 2011 | 213 | 0.040 |
Why?
| | Isoenzymes | 1 | 1999 | 23 | 0.040 |
Why?
| | Sodium Channels | 1 | 1999 | 1 | 0.040 |
Why?
| | Granulocytes | 1 | 1999 | 1 | 0.040 |
Why?
| | Receptors, Neurotensin | 1 | 1999 | 1 | 0.040 |
Why?
| | HL-60 Cells | 1 | 1999 | 1 | 0.040 |
Why?
| | Cholera Toxin | 1 | 1998 | 1 | 0.040 |
Why?
| | Veratridine | 1 | 1998 | 1 | 0.040 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily A | 1 | 2018 | 1 | 0.040 |
Why?
| | Interleukin-12 | 1 | 2018 | 3 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2018 | 2 | 0.040 |
Why?
| | STAT4 Transcription Factor | 1 | 2018 | 3 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 6 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 1 | 0.040 |
Why?
| | GRB2 Adaptor Protein | 1 | 2018 | 5 | 0.040 |
Why?
| | Purinergic Agonists | 1 | 1997 | 1 | 0.040 |
Why?
| | Intracellular Membranes | 1 | 1997 | 2 | 0.040 |
Why?
| | Cations | 1 | 1997 | 2 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 1997 | 5 | 0.040 |
Why?
| | Ion Channels | 1 | 1997 | 4 | 0.040 |
Why?
| | Adenylyl Cyclases | 1 | 1996 | 1 | 0.040 |
Why?
| | Estrenes | 1 | 1996 | 1 | 0.040 |
Why?
| | Pyrrolidinones | 1 | 1996 | 1 | 0.040 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 1996 | 4 | 0.040 |
Why?
| | Neuroblastoma | 1 | 1996 | 14 | 0.040 |
Why?
| | Enzyme Activation | 3 | 2004 | 12 | 0.040 |
Why?
| | Receptors, Cholinergic | 2 | 2010 | 2 | 0.030 |
Why?
| | Adenylyl Cyclase Inhibitors | 1 | 1996 | 1 | 0.030 |
Why?
| | Cell Polarity | 1 | 2015 | 1 | 0.030 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2015 | 1 | 0.030 |
Why?
| | Lymphoid Tissue | 1 | 2015 | 3 | 0.030 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2015 | 2 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2015 | 9 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2015 | 5 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 17 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 2015 | 12 | 0.030 |
Why?
| | Inflammation | 1 | 2015 | 49 | 0.030 |
Why?
| | Silver Staining | 1 | 2014 | 1 | 0.030 |
Why?
| | Calbindins | 1 | 2014 | 1 | 0.030 |
Why?
| | Brain Mapping | 1 | 2014 | 10 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2014 | 18 | 0.030 |
Why?
| | Protamines | 1 | 2014 | 1 | 0.030 |
Why?
| | Multiprotein Complexes | 1 | 2014 | 4 | 0.030 |
Why?
| | Albuminuria | 1 | 2014 | 12 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 16 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 130 | 0.030 |
Why?
| | Organ Culture Techniques | 2 | 2004 | 5 | 0.030 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2012 | 1 | 0.030 |
Why?
| | Cytochromes c | 1 | 2011 | 1 | 0.030 |
Why?
| | BH3 Interacting Domain Death Agonist Protein | 1 | 2011 | 1 | 0.030 |
Why?
| | Caspases | 1 | 2011 | 2 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 5 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 8 | 0.030 |
Why?
| | Endoplasmic Reticulum | 1 | 2011 | 3 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2011 | 3 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 14 | 0.030 |
Why?
| | Receptors, Purinergic P2X2 | 2 | 2001 | 2 | 0.020 |
Why?
| | Agrin | 1 | 2010 | 1 | 0.020 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 1 | 0.020 |
Why?
| | Tyrosine | 1 | 2010 | 4 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2010 | 11 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2010 | 3 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 19 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2010 | 13 | 0.020 |
Why?
| | Aged | 1 | 2012 | 411 | 0.020 |
Why?
| | Middle Aged | 1 | 2012 | 645 | 0.020 |
Why?
| | Young Adult | 1 | 2012 | 641 | 0.020 |
Why?
| | Adult | 1 | 2012 | 1199 | 0.020 |
Why?
| | Adolescent | 1 | 2012 | 2183 | 0.020 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2004 | 1 | 0.020 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2004 | 1 | 0.020 |
Why?
| | Enzyme Activators | 1 | 2004 | 1 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2004 | 4 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2004 | 2 | 0.020 |
Why?
| | COS Cells | 1 | 2004 | 19 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2004 | 12 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2004 | 23 | 0.020 |
Why?
| | Manganese | 1 | 2001 | 1 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2001 | 1 | 0.010 |
Why?
| | Nifedipine | 1 | 2001 | 1 | 0.010 |
Why?
| | Uridine Triphosphate | 1 | 2001 | 1 | 0.010 |
Why?
| | omega-Conotoxin GVIA | 1 | 2001 | 1 | 0.010 |
Why?
| | Thionucleotides | 1 | 2001 | 2 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 3 | 0.010 |
Why?
| | Thapsigargin | 1 | 2001 | 3 | 0.010 |
Why?
| | Cell Membrane | 1 | 2001 | 8 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 17 | 0.010 |
Why?
| | Cytosol | 1 | 2001 | 14 | 0.010 |
Why?
| | Plant Extracts | 1 | 2000 | 1 | 0.010 |
Why?
| | Ionomycin | 1 | 2000 | 1 | 0.010 |
Why?
| | Ionophores | 1 | 2000 | 3 | 0.010 |
Why?
| | Calcium Channels, N-Type | 1 | 2000 | 2 | 0.010 |
Why?
| | Antihypertensive Agents | 1 | 2000 | 12 | 0.010 |
Why?
| | Biological Transport | 1 | 2000 | 18 | 0.010 |
Why?
| | Melatonin | 1 | 1999 | 1 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1999 | 1 | 0.010 |
Why?
| | Scintillation Counting | 1 | 1999 | 1 | 0.010 |
Why?
| | Solvents | 1 | 1999 | 1 | 0.010 |
Why?
| | Solubility | 1 | 1999 | 2 | 0.010 |
Why?
| | Diffusion | 1 | 1999 | 4 | 0.010 |
Why?
| | Tryptamines | 1 | 1999 | 2 | 0.010 |
Why?
| | Water | 1 | 1999 | 6 | 0.010 |
Why?
| | Adrenergic beta-Agonists | 1 | 1999 | 5 | 0.010 |
Why?
| | Phospholipase C beta | 1 | 1999 | 1 | 0.010 |
Why?
| | Phospholipase C delta | 1 | 1999 | 1 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 151 | 0.010 |
Why?
| | Pyrazoles | 1 | 1999 | 3 | 0.010 |
Why?
| | Quinolines | 1 | 1999 | 6 | 0.010 |
Why?
| | Down-Regulation | 1 | 1999 | 14 | 0.010 |
Why?
| | Carbachol | 1 | 1996 | 1 | 0.010 |
Why?
| | Parasympathomimetics | 1 | 1996 | 1 | 0.010 |
Why?
| | Drug Synergism | 1 | 1996 | 7 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|